A Phase 2 interventional study of ARS-1 1 mg and Albuterol MDI in Asthma, sponsored by ARS Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by ARS Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,694 studies in Asthma with a site in United States — 134 open to participants now, 187 under way, 19 of them phase 3. Asthma · United States.
Among the 1,694 studies in Asthma with a site in United States, this one is the 1,162nd largest by enrollment of the 1,353 interventional ones that give a count, is one of 44 that started in 2022, is one of 292 in phase 2, and was the 1,486th registered.
4,846 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →134 of the 1,694 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 12–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,694 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 337 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 44 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 1,353 interventional studies, 113 across the 329 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
642 of 1,694 have an industry lead sponsor. The 10 most frequent:
ARS Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
ARS Pharmaceuticals, Inc. has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
84 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,694 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARS 2mg: albuterol: Placebo: ARS 1mg
Drug: ARS-1 1 mg · Drug: Albuterol MDI · Drug: Placebo · Drug: ARS-1 2mg
ARS 1mg: Placebo: albuterol: ARS 2mg
Drug: ARS-1 1 mg · Drug: Albuterol MDI · Drug: Placebo · Drug: ARS-1 2mg
ARS-1 1 mg
180 mcg
Placebo
ARS-1 2mg
Effect of ARS-1 Versus Albuterol and Placebo
Difference in forced expiratory volume in 1 second (FEV1) based on area under the curve (AUC)
Time frame: From baseline (timepoints 0) to 1 hour
| Milestone | Sequence 1 | Sequence 2 |
|---|---|---|
| Started | 12 | 6 |
| Completed | 12 | 6 |
| Not completed | 0 | 0 |
Difference in forced expiratory volume in 1 second (FEV1) based on area under the curve (AUC)
| FEV1 L per hour | ARS-1 1mg | ARS-1 2mg | Placebo | Albuterol |
|---|---|---|---|---|
| Effect of ARS-1 Versus Albuterol and Placebo | 0.150 ± 0.223 | 0.233 ± 0.216 | -0.002 ± 0.118 | 0.378 ± 0.265 |
Collected over 5 hours. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARS-1 1mg | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| ARS-1 2mg | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| Placebo | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Albuterol | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
| Event | ARS-1 1mg | ARS-1 2mg | Placebo | Albuterol |
|---|---|---|---|---|
| Nasal discomfortGeneral disorders | 5/18 | 7/18 | 1/18 | 0/18 |
| Age, Categorical(Participants) | Interventional Treatment |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 18 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Interventional Treatment |
|---|---|
| Female | 9 |
| Male | 9 |
| Race and Ethnicity Not Collected(Participants) | Interventional Treatment |
|---|
| Region of Enrollment(participants) | Interventional Treatment |
|---|---|
| United States | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Feb 2024, 18 months.
Results were first posted in Jul 2026, 2 years 5 months after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 18 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ARS Pharmaceuticals, Inc.